Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
株式のランク #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
株価
$4.74
最終同期: 2026-08-31
時価総額
$372.19M
変化(1日)
-2.47%
変化(1年)
-1.04%
US
取引 Lexeo Therapeutics, Inc. Common Stock (LXEO)

カテゴリー

Lexeo Therapeutics, Inc. Common Stock(LXEO)の配当利回りの履歴
Lexeo Therapeutics, Inc. Common Stock(銘柄コード: LXEO)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Lexeo Therapeutics, Inc. Common Stock(LXEO)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)